Merus Nv share price today
(NASDAQ: MRUS)

Name: Merus Nv Share Price Today (NASDAQ: MRUS) - Merus Nv Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Merus Nv share price is $41.11 & ₹3,555.60 as on 24 Jan 2025, 2.30 'hrs' IST

$41.11

▲

0.48

(1.18%)

Market is closed - opens 8 PM, 24 Jan 2025

View live Merus Nv share price in Dollar and Rupees. Guide to invest in Merus Nv stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Merus Nv, along with analyst recommendations, forecasts, and comprehensive financials.

Merus Nv share price movements

Today's Low: $40.00
Today's High: $41.33
$41.11
2.71%
Downside
Day's Volatility :3.23%
Upside
0.53%
52 Weeks Low: $33.60
52 Weeks High: $61.61
$41.11
18.27%
Downside
52 Weeks Volatility :45.46%
Upside
33.27%

Merus Nv Returns

Period	Merus Nv	Sector (Health Care)	Index (Russel 2000)
3 Months	-23.43%	-5.5%	0.0%
6 Months	-25.02%	-4.3%	0.0%
1 Year	19.15%	1.6%	0.0%
3 Years	54.43%	9.8%	-11.0%

Merus Nv Key Statistics

in dollars & INR

Previous Close	$40.63
Open	$40.15
Today's High	$41.33
Today's Low	$39.995
Market Capitalization	$2.7B
Today's Volume	$381.4K
52 Week High	$61.61
52 Week Low	$33.6
Revenue TTM	$35.9M
EBITDA	$-228.5M
Earnings Per Share (EPS)	$-4.06
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-44.6%

How to invest in Merus Nv Stock (MRUS) from India?

It is very easy for Indian residents to invest directly in Merus Nv from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Merus Nv stock in both Indian Rupees (INR) and US Dollars (USD). Search for Merus Nv or MRUS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Merus Nv or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Merus Nv shares which would translate to 0.021 fractional shares of Merus Nv as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Merus Nv, in just a few clicks!

Returns in Merus Nv for Indian investors in Rupees

Investment Value

₹1,00,000

Merus Nv investment value today

Current value as on today

₹1,24,612

Returns

₹24,612

(+24.61%)

Returns from Merus Nv Stock

₹20,557 (+20.56%)

Dollar Returns

₹4,054 (+4.05%)

Indian investors sentiment towards Merus Nv

-35%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for Merus Nv on INDmoney from India has reduced in the last 30 days as on Jan 24, 2025. -35% less investors are searching Merus Nv in the last 30 days versus the previous period.

Global Institutional Holdings in Merus Nv

FMR Inc
10.04%
RTW INVESTMENTS, LLC
6.09%
Deerfield Management Co
4.98%
COMMODORE CAPITAL LP
4.89%
Wellington Management Company LLP
4.22%
Samlyn Capital, LLC
3.81%

Analyst Recommendation on Merus Nv

Buy

95%Buy

5%Hold

0%Sell

Based on 20 Wall street analysts offering stock ratings for Merus Nv(by analysts ranked 0 to 5 stars)

Based on 20 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Merus Nv

What analysts predicted

Upside of 109.37%

Target:

$86.07

Current:

$41.11

Insights on Merus Nv

Price Movement
In the last 3 months, MRUS stock has moved down by -22.3%
Increasing Revenue
Revenue is up for the last 2 quarters, 7.33M → 11.77M (in $), with an average increase of 37.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -34.45M → -99.90M (in $), with an average decrease of 72.4% per quarter
MRUS vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 40.5% return, outperforming this stock by 23.1%
MRUS vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 95.4% return, outperforming this stock by 38.5%
Price to Sales
ForMRUS every $1 of sales, investors are willing to pay $69.6, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.1 for every $1 of sales.

Merus Nv Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$36.0M	↑ 141.72%
Net Income	$-27.8M	↓ 68.34%
Net Profit Margin	-77.17%	↑ 512.02%

	FY19	Y/Y Change
Revenue	$31.1M	↓ 13.46%
Net Income	$-55.2M	↑ 98.66%
Net Profit Margin	-177.15%	↓ 99.98%

	FY20	Y/Y Change
Revenue	$29.9M	↓ 3.82%
Net Income	$-85.5M	↑ 55.05%
Net Profit Margin	-285.59%	↓ 108.44%

	FY21	Y/Y Change
Revenue	$49.1M	↑ 64.0%
Net Income	$-66.8M	↓ 21.86%
Net Profit Margin	-136.06%	↑ 149.53%

	FY22	Y/Y Change
Revenue	$41.6M	↓ 15.32%
Net Income	$-131.2M	↑ 96.35%
Net Profit Margin	-315.48%	↓ 179.42%

	FY23	Y/Y Change
Revenue	$43.9M	↑ 5.68%
Net Income	$-154.9M	↑ 18.1%
Net Profit Margin	-352.56%	↓ 37.08%

	Q2 FY23	Q/Q Change
Revenue	$10.5M	↓ 22.39%
Net Income	$-32.0M	↓ 19.4%
Net Profit Margin	-305.78%	↓ 11.38%

	Q3 FY23	Q/Q Change
Revenue	$11.0M	↑ 5.32%
Net Income	$-23.0M	↓ 28.16%
Net Profit Margin	-208.57%	↑ 97.21%

	Q4 FY23	Q/Q Change
Revenue	$8.9M	↓ 18.98%
Net Income	$-60.2M	↑ 161.4%
Net Profit Margin	-672.93%	↓ 464.36%

	Q1 FY24	Q/Q Change
Revenue	$7.9M	↓ 11.75%
Net Income	$-34.5M	↓ 42.72%
Net Profit Margin	-436.76%	↑ 236.17%

	Q2 FY24	Q/Q Change
Revenue	$7.3M	↓ 7.06%
Net Income	$-50.0M	↑ 45.23%
Net Profit Margin	-682.52%	↓ 245.76%

	Q3 FY24	Q/Q Change
Revenue	$11.8M	↑ 60.56%
Net Income	$-99.9M	↑ 99.64%
Net Profit Margin	-848.67%	↓ 166.15%

	FY18	Y/Y Change
Profit	$35.7M	↑ 140.21%

	FY19	Y/Y Change
Profit	$-18.5M	↓ 151.77%

	FY20	Y/Y Change
Profit	$-27.4M	↑ 48.02%

	FY21	Y/Y Change
Profit	$-37.2M	↑ 35.66%

	FY22	Y/Y Change
Profit	$29.6M	↓ 179.67%

	FY23	Y/Y Change
Profit	$43.9M	↑ 48.45%

	Q2 FY23	Q/Q Change
Profit	$-15.5M	↓ 17.09%

	Q3 FY23	Q/Q Change
Profit	$-23.8M	↑ 53.89%

	Q4 FY23	Q/Q Change
Profit	$-27.9M	↑ 17.35%

	Q1 FY24	Q/Q Change
Profit	$7.3M	↓ 126.09%

	Q2 FY24	Q/Q Change
Profit	$7.3M	↑ 0.69%

	Q3 FY24	Q/Q Change
Profit	$11.8M	↑ 60.56%

	FY18	Y/Y Change
Operating Cash Flow	$-46.3M	↑ 3.21%
Investing Cash Flow	$-25.2M	↓ 39.54%
Financing Cash Flow	$59.0M	↓ 73.59%

	FY19	Y/Y Change
Operating Cash Flow	$-63.0M	↑ 36.09%
Investing Cash Flow	$24.2M	↓ 196.05%
Financing Cash Flow	$74.2M	↑ 25.79%

	FY20	Y/Y Change
Operating Cash Flow	$-79.9M	↑ 26.73%
Investing Cash Flow	$-1.5M	↓ 106.15%
Financing Cash Flow	$39.5M	↓ 46.76%

	FY21	Y/Y Change
Operating Cash Flow	$-59.6M	↓ 25.37%
Investing Cash Flow	$-146.6M	↑ 9766.96%
Financing Cash Flow	$282.0M	↑ 613.45%

	FY22	Y/Y Change
Operating Cash Flow	$-149.9M	↑ 151.39%
Investing Cash Flow	$2.8M	↓ 101.91%
Financing Cash Flow	$58.7M	↓ 79.17%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-41.6M	↑ 13.18%
Investing Cash Flow	$-24.5M	↑ 0.0%
Financing Cash Flow	$66.0M	↑ 30299.54%

Merus Nv Technicals Summary

Sell

Neutral

Buy

Merus Nv is currently in a neutral trading position according to technical analysis indicators.

Merus Nv Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Merus Nv	-5.73%	-25.02%	19.15%	54.43%	136.63%
Biontech Se	0.91%	34.01%	18.85%	-26.4%	246.9%
Regeneron Pharmaceuticals, Inc.	-4.82%	-36.95%	-28.33%	12.74%	100.35%
Vertex Pharmaceuticals Incorporated	4.86%	-13.58%	-0.46%	88.45%	88.24%
Alnylam Pharmaceuticals, Inc.	9.57%	13.5%	44.91%	103.56%	127.75%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Merus Nv	NA	NA	0.0	-3.75	-0.45	-0.22	NA	10.28
Biontech Se	160.8	NA	0.04	-3.33	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	17.02	17.02	1.05	44.99	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.1	0.48	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Merus Nv	Buy	$2.7B	136.63%	NA	0.0%
Biontech Se	Buy	$28.1B	246.9%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.6B	100.35%	17.02	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$110.2B	88.24%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$34.2B	127.75%	NA	-15.86%

Merus Nv Dividend announcements

Merus Nv Earnings
Merus Nv’s price-to-earnings ratio stands at None
Read More

About Merus Nv

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Organization	Merus Nv
Employees	172
CEO	Dr. Sven Ante Lundberg M.D.
Industry	Health Technology

Management People of Merus Nv

Name	Title
Dr. Sven Ante Lundberg M.D.	CEO, President & Executive Director
Mr. Gregory D. Perry	Chief Financial Officer
Mr. Peter B. Silverman J.D.	EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal
Dr. Hennie Hoogenboom	Co-Founder and Scientific Advisor
Harry Shuman	Chief Accounting Officer
Mr. Cornelis Adriaan de Kruif Ph.D.	CTO & Executive VP
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.	Chief Scientific Officer & Senior VP
Ms. Kathleen Farren	IR & Corporate Communications Officer
Ms. Audrey Bergan	Chief People Officer
Ms. Shannon Campbell	Executive VP & Chief Commercial Officer

Important FAQs about investing in Merus Nv (MRUS) from India :

What is Merus Nv share price today?

Merus Nv share price today stands at $41.11, Open: $40.15 ; Previous Close: $40.63 ; High: $41.33 ; Low: $40.00 ; 52 Week High: $61.61 ; 52 Week Low: $33.60. The stock opens at $40.15, after a previous close of $40.63. The stock reached a daily high of $41.33 and a low of $40.00, with a 52-week high of $61.61 and a 52-week low of $33.60.

Can Indians buy Merus Nv shares?

Yes, Indians can invest in the Merus Nv (MRUS) from India.

With INDmoney, you can buy Merus Nv at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Merus Nv at zero transaction cost.

How can I buy Merus Nv shares from India?

It is very easy to buy Merus Nv from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Merus Nv be purchased?

Yes, you can buy fractional shares of Merus Nv with INDmoney app.

What are the documents required to start investing in Merus Nv stocks?

To start investing in Merus Nv, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.